Eosinophil Peroxidase as a Dynamic Indicator of Treatment Response in Eosinophilic Chronic Rhinosinusitis
Eosinophil peroxidase (EPX) correlates with local type 2 inflammation and may serve as a noninvasive biomarker of eosinophilic chronic rhinosinusitis. EPX declines after surgery and dupilumab, highlighting its potential to track treatment response. High baseline EPX predicts patients likely to achieve a clinically meaningful Sinonasal Outcome Test-22 change.
Authors
- Patricia A. Loftus (ORCID: https://orcid.org/0000-0002-5785-183X)
- Andrew N. Goldberg (ORCID: https://orcid.org/0000-0002-0301-2926)
- Annabelle R. Charbit (ORCID: https://orcid.org/0000-0002-5799-0581)
- Jacquelyn K. Callander (ORCID: https://orcid.org/0000-0002-7266-9868)
- Steven D. Pletcher (ORCID: https://orcid.org/0000-0003-0127-927X)
- Monica Tang (ORCID: https://orcid.org/0000-0001-8847-5817)
- José Gurrola (ORCID: https://orcid.org/0000-0001-6801-5768)
- Camryn Marshall (ORCID: https://orcid.org/0000-0003-4151-2638)
- Kritika Khanna (ORCID: https://orcid.org/0000-0003-0463-8442)
- Andrew H. Murr
Institutions
- University of California, San Francisco (US)
- University of California System (US)
- Stanford University (US)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1002/alr.70076
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00